Osimertinib is a targeted therapy for EGFR-mutant non-small cell lung cancer. During treatment, close monitoring is required for interstitial lung disease/pneumonitis, cardiac toxicities (QTc prolongation, cardiomyopathy), and skin adverse reactions, with dose adjustment or discontinuation based on severity. This drug is primarily metabolized by CYP3A, and concomitant use with strong CYP3A4 inducers should be avoided. Pretreatment patient evaluation is needed, and patients should be informed of relevant risks and precautions.
Osimertinib Patient Monitoring
1. Monitor for symptoms of interstitial lung disease (ILD) and pneumonitis during treatment.
2. For patients with congenital long QT syndrome, congestive heart failure, or electrolyte abnormalities, and for those receiving concomitant medications known to prolong the QT interval, monitor for corrected QT (QTc) interval prolongation.
3. For patients with congenital long QT syndrome, congestive heart failure, or electrolyte abnormalities, and for those receiving concomitant medications known to prolong the QT interval, periodic monitoring of electrolyte concentrations is recommended.
4. For patients with cardiac risk factors receiving osimertinib monotherapy, and for all patients receiving osimertinib in combination with pemetrexed and platinum-based chemotherapy, cardiac monitoring (including LVEF assessment) should be performed during treatment. LVEF should be assessed in any patient who develops relevant cardiac signs or symptoms during treatment.
5. Perform complete blood count (CBC) with differential periodically during treatment, and increase the frequency as clinically indicated.
Osimertinib Dose Modifications for Adverse Reactions
1. Pulmonary
(1) For patients who have not received recent definitive platinum-based chemoradiotherapy, permanently discontinue osimertinib if any grade of ILD or pneumonitis occurs.
(2) For patients who have received recent definitive platinum-based chemoradiotherapy, withhold or continue osimertinib as clinically indicated for Grade 1 ILD/pneumonitis. Permanently discontinue osimertinib for Grade ≥2 ILD/pneumonitis in these patients.
2. Cardiac
(1) If QTc interval >500 msec on at least two separate ECGs, withhold treatment.
(2) Permanently discontinue osimertinib if QTc prolongation is accompanied by signs/symptoms of life-threatening arrhythmia.
(3) Permanently discontinue osimertinib if symptomatic congestive heart failure occurs.
3. Skin Toxicity
(1) Withhold osimertinib if Stevens-Johnson syndrome, toxic epidermal necrolysis, or bullous erythema multiforme is suspected. If confirmed, permanently discontinue osimertinib.
(2) Withhold osimertinib if cutaneous vasculitis is suspected, and evaluate the patient for systemic involvement; consider dermatology consultation. If no other etiology is identified, consider permanent discontinuation of osimertinib based on severity.
4. Hematologic and Bone Marrow Toxicity
Withhold osimertinib if aplastic anemia is suspected. If confirmed, permanently discontinue osimertinib.
5. Other Toxicities
(1) For other Grade 3 or higher adverse reactions, withhold treatment for up to 3 weeks.
(2) If the adverse reaction improves to Grade 0-2, resume at the same dose or a reduced dose (40 mg once daily); if no improvement within 3 weeks, permanently discontinue osimertinib.
Osimertinib Coadministration with CYP3A Inducers
Avoid concomitant use of osimertinib with strong CYP3A4 inducers. If concomitant use with a strong CYP3A4 inducer is unavoidable, increase osimertinib dose to 160 mg once daily. After discontinuation of the strong CYP3A4 inducer for 3 weeks, resume the usual dose of 80 mg once daily.
Osimertinib in Combination with Pemetrexed and Platinum-Based Chemotherapy
When osimertinib is administered concurrently with pemetrexed and platinum-based chemotherapy, adjust the dose of any of these treatments as needed for adverse reaction management. For specific osimertinib dose modifications, refer to the "Dose Modifications" section above. Withhold, reduce, or permanently discontinue pemetrexed, cisplatin, or carboplatin according to their respective prescribing information.
